Core Points - Jiangsu Sihuan Biological Co., Ltd. held its 15th meeting of the 10th Board of Directors on June 13, 2025, to discuss important company matters [1] - The company appointed Liu Zhijiang as the new Chief Financial Officer, effective from the date of the board's approval until the end of the current board's term [1] Summary by Sections - **Board Meeting Details** - The 15th meeting was conducted in a hybrid format, combining in-person and communication methods [1] - The meeting was legally valid as it met the attendance requirements set forth in the company's articles of association [1] - **Appointment of CFO** - Liu Zhijiang was nominated by General Manager Chen Long and approved by the Board's Nomination Committee and Audit Committee [1] - The appointment is documented in a separate announcement regarding the resignation and hiring of the CFO [1]

武汉科前生物股份有限公司 2025 年第二次临时股东大会会议材料 武汉科前生物股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》以及《武汉科前生物股份有限公司章程》《武汉科前生物股 份有限公司股东大会议事规则》等相关规定，特制定 2025 年第二次临时股东大 会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件须加盖公司公章，经验证后，方可出席会议。 会议开始后,由会议主持人宣布现场出席会议的股东人数及其所持有表决权 的股份总数，在此之后进场的股东无权参与现场投票表决。 ...

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has obtained a new veterinary drug registration certificate for "Prednisolone Tablets," marking a significant advancement in the treatment of canine allergic and inflammatory diseases [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug, "Prednisolone Tablets," is classified as a Category V new veterinary drug and is approved for treating allergic and inflammatory diseases in dogs, including non-specific eczema, summer dermatitis, and allergic conditions [2][3]. - The drug is developed by a consortium of companies, including Qingdao Weilan Biological Co., Ltd. and its subsidiaries, with a total research and development investment of 1.7444 million yuan [2][3]. Group 2: Market Background - Skin diseases have the highest incidence among pet diseases, particularly in dogs, with recurrent skin conditions accounting for over 75% of total incidence rates [2][3]. - There is a limited variety of drugs available for treating inflammatory skin diseases in pets, primarily relying on glucocorticoids, which have significant side effects and metabolic burdens [3][4]. Group 3: Drug Development and Impact - Prednisolone is a modified glucocorticoid with four times the anti-inflammatory activity of hydrocortisone and reduced sodium retention, making it suitable for animals with liver dysfunction [3][4]. - The approval of the new veterinary drug reflects the company's commitment to technological innovation and is expected to create new growth opportunities for the business [4].

武汉科前生物股份有限公司 董事会提名委员会 综上，董事会提名委员会一致同意提名罗知女士为公司第四届董 事会独立董事候选人，并同意将该议案提交至公司第四届董事会第十 一次会议、2025年第二次临时股东大会审议。 武汉科前生物股份有限公司 董事会提名委员会 根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》《上市公司独立董事管理办法》及《武汉 科前生物股份有限公司章程》等有关规定，公司第四届董事会提名委 员会对第四届董事会独立董事候选人罗知女士的任职资格进行了审核 并发表审核意见如下： 经审阅公司第四届董事会独立董事候选人罗知女士的个人履历等 相关资料，认为上述独立董事候选人的任职资格符合相关法律、法规、 规范性文件对董事任职资格的要求，不存在《公司法》、《武汉科前 生物股份有限公司章程》规定的不得担任公司董事的情形，上述独立 董事候选人未受到中国证券监督管理委员会的行政处罚或交易所惩戒， 不存在上海证券交易所认定不适合担任上市公司董事的其他情形。 此外，独立董事候选人的教育背景、工作经历、专业能力等均能 够胜任独立董事的职责要求，符合《上市公司独立董事管理办法》以 及公司《独立董 ...

Group 1 - The core point of the announcement is the decision made by the Supervisory Board of Wuhan Keqian Biological Co., Ltd. to approve a cooperation research and development agreement with Huazhong Agricultural University, which is considered to align with the company's overall development direction [1][2] - The meeting was held on June 10, 2025, via telecommunication voting, with all three participating supervisors voting in favor of the proposal [1][2] - The Supervisory Board confirmed that the approval process for the related party transaction is legal and compliant, and does not harm the interests of the company or its shareholders [1]

证券代码：688526 证券简称：科前生物 公告编号：2025-032 武汉科前生物股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 26 日 14 点 00 分 二、 会议审议事项 召开地点：湖北武汉东湖新技术开发区高新二路 419 号科前生物二楼会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 26 日 至2025 年 6 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投 ...

Core Viewpoint - The legal opinion issued by Beijing Yongxing Law Firm confirms that the 2025 Restricted Stock Incentive Plan of Baolingbao Biological Co., Ltd. has obtained the necessary approvals and complies with relevant regulations [4][8]. Group 1: Approval and Authorization - The company has completed the necessary procedures for the approval of the incentive plan, including discussions at the sixth board meeting and the issuance of relevant opinions by the remuneration and assessment committee [5][6]. - The plan has been publicly disclosed, and no objections were raised during the public notice period [6][8]. Group 2: Specifics of the Grant - The grant date for the incentive plan is set for June 9, 2025, with a grant price of 3.92 RMB per share for 10.35 million shares to 50 eligible participants [8]. - The conditions for granting the restricted stock include compliance with various financial and regulatory requirements, ensuring that the company and the participants do not fall under any disqualifying circumstances [9]. Group 3: Conclusion - The legal opinion concludes that all necessary approvals and authorizations have been obtained, and the grant date, recipients, and pricing are in accordance with the applicable regulations [8][9].

证券代码：600201 证券简称：生物股份 公告编号：临2025-034 金宇生物技术股份有限公司 关于转让投资基金份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）于 2015 年 10 月与其他合伙 人共同投资北京中技华科创业投资合伙企业（有限合伙）（以下简称"基金"或"中 技华科"）。基金认缴出资总额为 5.10 亿元，公司作为有限合伙人参与投资，认缴 出资金额 2 亿元，占其总规模的 39.2157%。 根据公司整体投资规划安排，公司与北京金陵华瑞咨询合伙企业（有限合伙） （以下简称"金陵华瑞"）签署了《财产份额转让协议》，将其持有的中技华科的 26.4706%的财产份额转让给金陵华瑞，转让价款为 13,500 万元。本次基金投资份 额转让完成后，公司持有基金份额 6,500 万份。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。根据《上海证券交易所股票上市规则》及《公司章程》等相关规 定，本次转让基金份额事项无需提交董事会审 ...

Core Viewpoint - The company announced the transfer of a 26.4706% stake in a venture capital partnership for a total consideration of 135 million yuan [1] Group 1 - The company will transfer its stake in Beijing Zhongji Huake Venture Capital Partnership to Beijing Jinling Huarui Consulting Partnership [1] - The transfer price is set at 135 million yuan [1] - After the transfer, the company will still hold 65 million shares in the fund [1]

Core Points - The article outlines the implementation details of the Audit Committee established by Jiangsu Sihuan Bioengineering Co., Ltd. to enhance the decision-making function of the board and ensure effective supervision of the management team [2][3] Group 1: General Provisions - The Audit Committee is a specialized working body set up by the board of directors to exercise the powers of the supervisory board as stipulated in the Company Law [2] - The committee is responsible for reviewing financial information, supervising internal and external audits, and evaluating internal controls [2][3] Group 2: Composition of the Committee - The Audit Committee consists of three directors, including two independent directors, with an independent director who is a financial professional serving as the convener [3][4] - The committee members are nominated by the chairman or a majority of independent directors and elected by the board [3][4] Group 3: Responsibilities and Authority - The main responsibilities include reviewing financial reports, supervising external and internal audits, and ensuring compliance with laws and regulations [4][5] - The committee must approve significant financial disclosures and the hiring or dismissal of external auditors before submission to the board [4][5] Group 4: Decision-Making Procedures - The Audit Department prepares written materials for the committee's decision-making, including financial reports and audit findings [7][8] - Regular meetings are held at least quarterly, with provisions for emergency meetings as needed [8][9] Group 5: Meeting Rules - Meetings require the presence of at least two-thirds of the committee members to be valid, and decisions are made by a majority vote [8][9] - The committee may invite external experts for professional opinions if necessary [9] Group 6: Supplementary Provisions - The implementation details take effect upon approval by the board and are subject to relevant national laws and regulations [10]